XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Apr. 30, 2020
Cash flows from operating activities:          
Net loss $ (3,151) $ (2,919) $ (9,560) $ (9,133)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Foreign exchange (gain)/loss (3) 1 (13) 5  
Depreciation of fixed assets     106 117  
Amortization of right of use asset     159 146  
Compensation expense related to stock option grants and restricted stock 115 56 338 225  
Gain due to the change in fair value of warrant liabilities (6)  
Loss on disposal of property, plant and equipment     2  
Changes in operating assets and liabilities:          
Accounts receivable     105 (7)  
Contract assets     188 (20)  
Other assets     (310) 19  
Accounts payable     (473) (194)  
Accrued expenses     1,192 257  
Change in lease liability     (169) (147)  
Contract liabilities     (90) 107  
Net cash used in operating activities     (8,525) (8,631) $ 10,500
Cash flows from investing activities:          
Purchase of property, plant and equipment     (17) (61)  
Net cash used in investing activities     (17) (61)  
Cash flows from financing activities:          
Proceeds from Paycheck Protection Program Loan     890  
Proceeds from loan payable     467  
Payment of loan payable     (292)  
Proceeds from stock option exercises     40  
Proceeds from issuance of common stock- Aspire financing net of issuance costs     9,983 850  
Proceeds from issuance of common stock- AGP At The Market offering, net of issuance costs     66,166 1,520  
Proceeds associated with exercise of common stock warrants     769  
Proceeds (costs) associated with exercise of pre-funded warrants     (16)  
Acquisition of treasury stock     (36) (1)  
Net cash provided by financing activities     77,987 2,353  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     32 (15)  
Net increase/(decrease) in cash, cash equivalents and restricted cash     69,477 (6,354)  
Cash, cash equivalents and restricted cash, beginning of period     10,930 17,159 17,159
Cash, cash equivalents and restricted cash, end of period $ 80,407 $ 10,805 80,407 10,805 $ 10,930
Supplemental disclosure of noncash operating activities:          
Prepaid financing costs reported in accrued expenses     62 13  
Supplemental disclosure of noncash investing activities:          
Acquisition of property, plant and equipment through accounts payable     9  
Supplemental disclosure of noncash financing activities:          
Common stock issued for payment of commitment fee     295  
Outstanding receivable for sale of shares through AGP at the Market program     271  
Outstanding receivable for sale of shares from warrant exercises     1,838  
Outstanding receivable for sale of shares from stock option exercises     $ 144